Gold marker displacement due to needle insertion during HDR-brachytherapy for treatment of prostate cancer: A prospective cone beam computed tomography and kilovoltage on-board imaging (kV-OBI) study

Table 1 Characteristics of patients entered this in study

Age	72,5 (57-77)
Tumor stage
T1c	3 (17%)
T2a	2 (11%)
T2b	3 (17%)
T2c	8 (44%)
T3a	2 (11%)
Nodal stage
N0	16 (89%)
N+	2 (11%)
Gleason Score
≤ 6	9 (50%)
7	6 (33%)
≥ 8	3 (17%)
PSA-Level initial
< 10	10 (56%)
10-20	1 (6%)
> 20	7 (39%)
Previous treatment
no hormonal ablative therapy	9 (50%)
hormonal ablative therapy	9 (50%)
Treatment volume
prostate only	12 (67%)
whole pelvis	6 (33%)

ISSN: 1748-717X